Clinical Oncology Books

[Lara Preece]

Thispopular textbook provides a clear and comprehensive introduction to the principles and practice of clinical oncology. Ideal for medical undergraduates, clinicians and other health professionals who want to increase their understanding of the challenges of managing patients with cancer, the book enables readers to learn and then test themselves on all aspects of cancer medicine, from epidemiology, aetiology, pathogenesis and presentation, through to diagnosis, staging, management and prognosis.

Peter Hoskin is Consultant in Clinical Oncology at Mount Vernon Hospital, Northwood, London and Professor in Clinical Oncology at University College London, UKRobert Glynn Jones is Consultant in Clinical Oncology at Mount Vernon Hospital, Northwood, London, UKPeter Ostler is Consultant in Clinical Oncology and Divisional Lead at Mount Vernon Hospital, Northwood, London, UK

Produced under the direction of ESMO, the Handbooks series is intended to appeal to all healthcare professionals working in oncology. The handbooks are comprehensive guides which provide concise, first-hand advice in a practical, easy-to-read format.

This handbook describes the major types of malignancy which might occur during this transitional phase of life. It provides diagnostic and therapeutic guidance and also gives an idea of life after cancer. ESMO and SIOP Europe share the same goal: that no young person should have to die of cancer.

This handbook brings together specialists in the field of precision medicine, who have shared their knowledge and given their insights on this broad topic, providing you with a solid base to understand this field from basic science to clinical application.

This handbook enables all of us to read between the lines of a scientific publication, to better estimate the true benefit of a new oncological intervention and to better understand other cancer-related research.

The aim of the present edition of the ESMO Handbook of Oncological Emergencies is to approach the new advances and developments in the field of oncological emergency treatments, for the benefit of oncology specialists, but also for those who are just starting out in this profession.

This Handbook is a rare attempt to make an appraisal of where we are in the field of cancer diagnosis and treatment evaluation, by focusing on some key issues of the clinical method of medical oncologists.

The treatment of any patient, in particular seniors, requires a careful evaluation of the person who is in need of such treatment. This handbook focuses on the delicate decision-making process, which should lead to the best therapy, adapted not only to the disease but also to the person who suffers from it

In this ESMO Handbook the editors cover topics including the emerging processes of evading tumour destruction and tumour inflammation, new challenges posed by tumour heterogeneity, and new study designs and technologies.

This is a user-friendly handbook, designed for young medical oncologists, where they can access the essential information they need for providing the treatment which could have the highest chance of being effective and tolerable.

The site is secure.

The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Recently, a wide spectrum of artificial intelligence (AI)-based applications in the broader categories of digital pathology, biomarker development, and treatment have been explored. In the domain of digital pathology, these have included novel analytical strategies for realizing new information derived from standard histology to guide treatment selection and biomarker development to predict treatment selection and response. In therapeutics, these have included AI-driven drug target discovery, drug design and repurposing, combination regimen optimization, modulated dosing, and beyond. Given the continued advances that are emerging, it is important to develop workflows that seamlessly combine the various segments of AI innovation to comprehensively augment the diagnostic and interventional arsenal of the clinical oncology community. To overcome challenges that remain with regard to the ideation, validation, and deployment of AI in clinical oncology, recommendations toward bringing this workflow to fruition are also provided from clinical, engineering, implementation, and health care economics considerations. Ultimately, this work proposes frameworks that can potentially integrate these domains toward the sustainable adoption of practice-changing AI by the clinical oncology community to drive improved patient outcomes.

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

ASCO offers educational resources for cancer physicians and other health care professionals of clinical oncology. These include scientific meetings, educational conferences, professional workshops, and special symposia on issues of particular relevance and importance to oncologists and researchers. It also produced the patient information website, Cancer.Net.

It publishes numerous journals, books, newsletters, and online and multimedia resources; it publishes the Journal of Clinical Oncology (JCO),[2] the JCO Oncology Practice (JCO OP),[3] and the JCO Global Oncology (JCO GO),[4] JCO Clinical Cancer Informatics, which publishes clinically relevant research based on biomedical informatics methods and processes applied to cancer-related data, information, and images,[5] and JCO Precision Oncology, which publishes original research, reports, opinions, and reviews related to precision oncology and genomics-driven care of patients with cancer.[6]

Created by members of ASCO, the Conquer Cancer Foundation of ASCO is a 501(c)(3) charitable organization. Since the inception of its grants and awards program in 1984, Conquer Cancer has awarded more than $90 million in funding through nearly 1,500 grants and awards to researchers in 65 countries. In 2015, the foundation launched The Campaign to Conquer Cancer, a comprehensive campaign to raise $150 million to fund cancer research, support Conquer Cancer's top priorities, and bring national awareness to the Foundation.

ASCO's patient information website, Cancer.NET, is supported by the Conquer Cancer Foundation of ASCO. Cancer LINQ is ASCO's data platform initiative. It was created to give oncologists a robust quality monitoring system that collects and analyzes data from all patient encounters to improve quality of care. ASCO published its Value Framework in 2015 [9] and updated it in 2016.[10] This provides physicians and patients with a tool to assess and compare the value of different drugs in an era of skyrocking anticancer drug costs.[11]

All questions included on the examination are referenced from one or more items included on this list. The reference list is divided into categories to help make the list more manageable and to help you prioritize study time. Please be aware that the categories do not represent the proportionate use of the references." -Source: ACVIM Oncology Reading List

"The following texts may have more detail and different perspectives on important oncologic topics or contain specialized information that is not available elsewhere and may be complementary to Group 1." - ACVIM Oncology Reading List

"Candidates are expected to have a good working knowledge of the veterinary cancer literature. Publications containing material not yet available in textbooks are especially important. Each journal listed below should be reviewed for relevant articles from 2010 to present. Both print and online journal versions should be reviewed (including early view)." - ACVIM Oncology Reading List

"Candidates are responsible for relevant articles on veterinary oncology published in non-veterinary journals and review articles discussing major concepts in cancer biology and general therapeutic strategies. This list is not exhaustive." - ACVIM Oncology Reading List

A typical day and week in my practice: After 29 years of community practice in a small town, I recently switched to full-time academic practice. As opposed to my previous life, where I practiced general adult hematology and oncology, I now focus on head and neck and lung cancers.

The first patient is usually ready to be seen around 8:30 a.m. The day continues to evolve and usually ends around 4 p.m. when all the patients for the day have been taken care of. I often utilize my lunch break for attending scheduled meetings and lectures and for answering emails or returning phone calls. I usually complete charting and dictations after I have taken care of all my patients for the day.

At various times, oncology fellows, internal medicine residents or medical students join me in the clinic. It makes it more interesting and challenging as I try to share knowledge and clinical pearls commensurate with their individual level of training. At each encounter, I hope they learn about the high honor and privilege of being a physician and how to make an effort to prove equal to the task.

Late afternoon, we have multidisciplinary head-and-neck tumor board on Monday and the lung cancer tumor board on Thursday, where we discuss all new and challenging patients for the week, review their pathology, imaging, clinical course and reach a consensus on their management. This is in addition to discussing patients with fellow physicians on a daily basis, as the situation arises.

Some afternoons I make time for research and campus leadership meetings. If time allows, I may prepare a talk or a lecture on topics that fall in my domain. I also dedicate some time for AMA, American College of Physicians and Arkansas Medical Society meetings since I serve in leadership positions in those physician organizations.

3a8082e126